期刊
CHEMISTRY & BIOLOGY
卷 21, 期 5, 页码 666-678出版社
CELL PRESS
DOI: 10.1016/j.chembiol.2014.02.021
关键词
-
资金
- Canadian Institutes of Health Research (CIHR MOP) [97954, CIHR GPG-102171]
- Cystic Fibrosis Canada (CFC)
- CFC
- CIHR
- Dutch Cystic Fibrosis Society
- Wilhelmina Research Fund
- Peterborough K.M. Hunter Studentship
- Ontario Graduate Studentship
- National Institutes of Health [P30 CA125123]
The most common mutation causing cystic fibrosis (CF), F508del, impairs conformational maturation of CF transmembrane conductance regulator (CFTR), thereby reducing its functional expression on the surface of epithelia. Corrector compounds including C18 (VRT-534) and VX-809 have been shown to partially rescue misfolding of F508del-CFTR and to enhance its maturation and forward trafficking to the cell surface. Now, we show that there is an additional action conferred by these compounds beyond their role in improving the biosynthetic assembly. In vitro studies show that these compounds bind directly to the metastable, full-length F508del-CFTR channel. Cell culture and patient tissue-based assays confirm that in addition to their cotranslational effect on folding, certain corrector compounds bind to the full-length F508del-CFTR after its partial rescue to the cell surface to enhance its function. These findings may inform the development of alternative compounds with improved therapeutic efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据